Zie ook literatuurlijst niet-toxische middelen en behandelingen specifiek bij baarmoederkanker en baarmoederhalskanker van arts-bioloog drs. Engelbert Valstar. 

9 mei 2022: zie ook dit artikel dat  ik van een update heb voorzien: https://kanker-actueel.nl/coriolus-versicolor-bestrijdt-succesvol-hpv-virus-bij-patienten-met-baarmoederhalstumoren-en-reduceert-grootte-tumoren-en-graad-van-kwaadaardigheid-na-1-jaar-was-91-van-het-hpv-virus-verdwenen-in-suppletiegroep.html

18 december 2021: Zie ook dit artikel: https://kanker-actueel.nl/coriolus-versicolor-blijkt-effectief-natuurlijk-middel-tegen-hpv-virus.html

18 december 2021: Bron:  2021 Apr; 25(2): 130–136.

Een vaginale gel gebaseerd op Coriolus versicolor bij vrouwen met HPV = humaan papillomavirus gerelateerde baarmoederhalsinfecties en tumoren is veel effectiever in het laten verdwijnen van tumoren en HPV - infecties dan een gecontroleerde conventionele benadering (N = 59 vs 44 patiënten) blijkt uit de resultaten van de PALOMA studie, een multicenter, open-label, gerandomiseerde parallelgroep.

Het percentage patiënten met een normaal uitstrijkje en vergelijkende colposcopie 3 en 6 maanden na behandeling (respectievelijk 78,0% en 84,9%) waarbij de HPV infectie was verdwenen was significant hoger dan zonder behandeling (54,8% en 64,5%), vooral bij hoog-risico HPV-patiënten (79,5% en 87,8% versus 52,0% en 56,0%). Na een bezoek van 6 maanden werd de algehele HPV-infectie verwijdering bereikt door een groter aantal patiënten dat werd behandeld (59,6%) in vergelijking met patiënten zonder behandeling (41,9%), vooral bij HPV-patiënten met een hoog risico (62,5% versus 40,0%).

De onderzoekers concluderen: Behandeling met Papilocare heeft een beter klinisch voordeel aangetoond dan de conventionele waakzame benadering in de klinische praktijk voor HPV-patiënten met een totaal en hoog risico in termen van werkzaamheid om HPV-gerelateerde cervicale laesies te behandelen en om alle HPV-stammen te verwijderen na een enkele 6-maandelijkse periode. Het heeft een adequate veiligheid en verdraagbaarheid aangetoond en biedt extra voordelen zoals een hogere re-epithelisatie, stressvermindering en een hoge therapietrouw.

Het volledige studierapport is gratis in te zien. Klik op de titel voor het abstract:


The aim of the study was to evaluate the efficacy of Papilocare, a Coriolus versicolor–based vaginal gel, in repairing human papillomavirus (HPV)-related low-grade cervical lesions.


The study is a multicenter, open-label, randomized, parallel-group, watchful waiting approach-controlled trial involving 91 HPV-positive women with low-grade Pap smear alterations and consistent colposcopy.


The percentage of patients with normal Pap smear and concordant colposcopy 3 and 6 months after receiving treatment (78.0% and 84.9%) was significantly higher than without treatment (54.8% and 64.5%), especially in high-risk HPV patients (79.5% and 87.8% vs 52.0% and 56.0%). At 6-month visit, overall HPV clearance was achieved by a greater number of patients receiving treatment (59.6%) compared with those without treatment (41.9%), especially high-risk HPV ones (62.5% vs 40.0%). The cervical re-epithelization score was significantly higher with treatment (mean = 4.5) than without (mean = 4.1). Compared with baseline, perceived stress decreased in the treatment group (from 21.1 to 19.0) and increased in the control group (from 17.7 to 20.7). A total of 7 possible or probable treatment-related adverse events were reported, most of them (n = 6) being mild or moderate in severity.


Treatment with Papilocare has demonstrated a better clinical benefit than the conventional watchful waiting approach in clinical practice for total and high-risk HPV patients in terms of its efficacy to treat HPV-related cervical lesions and to clear all HPV strains after a single 6-month period. It has demonstrated an adequate safety and tolerability and confers additional benefits such as higher re-epithelization, stress reduction, and high treatment adherence.


Approximately 30% of Spanish women younger than 30 years are HPV carriers. The likelihood of HPV infection decreases over time, from 47% between the ages of 15 and 19 years to 12% in women older than 45 years. The HPV is a fundamental factor for the development of cervical cancer. The World Health Organization has recently established the elimination of cervical cancer as a priority medium-term objective. This trial aimed to explore whether treatment with Papilocare provides better results than the conventional watchful waiting strategy in improving low-grade cervical lesions, which are the first step in the natural history of cervical cancer. Clearance of LSILs after a conservative approach is of approximately 59% within 2 years of the diagnosis. Nevertheless, the likelihood of progression of these lesions to a high-grade squamous intraepithelial lesion within 5 years is 12.7%. In addition, treatments for cervical cancer severely compromise the reproductive health of women. In a systematic review of Cochrane, Kyrgiou et al. demonstrated a higher baseline risk for prematurity in women with cervical intraepithelial neoplasia, which increased with excisional and ablative treatments. Therefore, the scenario is conflicting, as choosing an excisional or ablative approach for the treatment of LSILs can result in negative reproductive outcomes, but avoiding treatment and just monitoring the disease results in its progression to high-grade lesions in 12 of 100 women. The current recommendation in Spain also includes monitoring the disease., However, based on the results of this present study, a novel strategy involving Papilocare has become available. The results of this treatment in the repair of low-grade lesions have demonstrated to significantly exceed those obtained with the watchful waiting approach (8 in 10 women achieved a normalization in their lesions).

Spontaneous clearance of the HR HPV occurs in approximately 29% and 41% of cases at 6 and 18 months, respectively. The HPV clearance rates seen in our study were higher, i.e., more than twice (63%) the established value at 6 months. This finding has important clinical implications considering the fact that the only guidelines that a physician can provide to their female patients to clear HPV is to maintain their vaginal health or, in the case or active smokers, to quit smoking. This absence of solutions may increase stress levels in many women. Indeed, the results of our study revealed a differential trend with respect to perceived stress, with increased reported levels in the control group and reduced ones in the treatment group. Thus, based on the results of our study, we believe that Papilocare should be included among the advices for the treatment of HPV considering its ability to double the clearance rate of HR HPV.

The results of our study have been replicated in several independent, observational, noncontrolled studies performed in Spanish public university hospitals. The 6-month effectiveness of Papilocare was evaluated and confirmed in all of the studies (between 53% and 72.5% of cases achieved a negative cytology and/or HPV clearance/reduced viral load). An update of the study by Riera et al., which included a watchful waiting control group, revealed a significantly higher percentage of responders in the group treated with Papilocare compared with the controls (80.0% vs 51.4%). Recent interim results from the observational, multicenter, prospective, single-cohort PAPILOBS study (#NTC04199260) revealed a notable effect of Papilocare at 6 months in repairing HPV-dependent low-grade cervical lesions and clearing HPV (66% and 63% of patients, respectively) under real-life conditions. Data obtained in the present study in relation to the HPV clearance, especially in HR HPV patients, are consistent with real-world data obtained in other studies. Moreover, in this trial, the degree of cervical re-epithelization was significantly higher with Papilocare compared with the control group. This beneficial effect on re-epithelization was also observed by Palacios et al. in a pilot study performed with 21 asymptomatic non–HPV-infected women, in which women treated Papilocare achieved improved cervical re-epithelization (from 3.1 to 4.4 according to the same cervical epithelization scoring system used in the present study). Similarly, Gálvez et al. reported a significant 20% improvement in cervical re-epithelialization in HPV-positive lesion-free women treated with Papilocare (3.8 vs 4.5) compared with baseline.

In addition, treatment with Papilocare is safe, as most AEs reported in this study were mild or moderate in severity. Moreover, most of the participants were satisfied with the treatment, and therapeutic adherence exceeded 90%. Nevertheless, our study has certain limitations: (1) the lack of information about cofactors for the progression of cervical HPV infection to cancer, such as smoking (lacking in the present study), or adjusting all analyses by covariables in patients, which could have avoided potential interferences in the results, and (2) it should be noted that we used a cytology plus concordant colposcopic observations to evaluate the normalization of lesions. Biopsies were not performed in the study because all women presented low-grade cytological alterations with normal colposcopy or grade 1 changes, decision in agreement with guidelines recommendations,, and also because biopsy can modify the natural history of the lesion. Thus, the present article does not provide evidence on the treatment and prevention of dysplasia; (3) colposcopic concordance and epithelization assessments were also performed in an unblinded manner; thus, subjectivity associated with these outcomes could have resulted in an assessment bias; (4) the “partial clearance” was included as part of the overall HPV clearance secondary end point (see method section) according to the concept that 1 HPV-related lesion is very frequently caused by just 1 viral subtype, despite the presence of multiple HPV types. With regression of the lesion as well as clearance of one of the oncogenic HPV subtypes, it is likely that the causative virus has been eliminated. Nevertheless, the risk of future lesions and dysplasia remains if the residual HPV subtype is a HR HPV, (5) Given the exploratory nature of the study and the concomitant determination of the sample size, the number of patients was insufficient for identifying statistical differences in certain secondary variables for which tendencies were observed. (6) Moreover, for our initial exploration, we aimed to analyze all women, not only those with HR HPV, and to obtain results that could be extrapolated for the general population. Additional subanalyses that already were planned in the protocol will determine the efficacy and safety of Papilocare on HR HPV patients. Further ongoing clinical trials have already included only HR HPV patients (the PAPILOCAN clinical trial #NCT04210336 and the PALOMA II clinical trial #NTC04199078). Besides these limitations, comparisons made with the conventional approach applied in standard clinical practice are very useful and provide evidence that new interventions for the management of HPV are required.


Treatment with Papilocare has demonstrated a better clinical benefit than the conventional watchful waiting approach in clinical practice for HPV-positive patients, especially for those with HR HPV. Papilocare has shown significant efficacy in the treatment of low-grade cervical lesions associated with HPV and a positive trend in increasing HPV clearance after a 6-month period. Moreover, it shows good safety and tolerability and confers additional benefits, such as a significant improvement in cervical re-epithelization, a positive trend in perceived stress reduction, and high therapeutic adherence.


The authors thank all the people and institutions that collaborated in developing this project, including Dr Juan Carlos Martínez Escoriza of Hospital General Universitario, Alicante, Spain; Dr Juan José Hernández, Dr Ester Martínez, and Dr Gema Aguión of Hospital Universitario Infanta Leonor, Madrid, Spain; Dr Jessica Martín, Dr Carmen González, Dr José Carlos Vilches, and Dr Laura López of Hospital Quironsalud, Málaga, Spain, for their cooperation as coinvestigators; Dr Alfonso Alba of Instituto de Estudios Celulares y Moleculares, Lugo, Spain, for his excellent work at the centralized laboratory; Dr Fernando Losa for his contributions during the drafting of the manuscript; Andrea Moral (project leader of the CRO Adknoma Health Research SL, Barcelona, Spain) for her invaluable operative support during the entire study; and Procare Health Iberia SL for financially supporting the project and its total transparency in all proceedings.


J.C. declares that he has received travel and/or research grants and/or honoraria for conferences and/or consultancy fees from Genómica, GSK, Merck, Procare Health, Qiagen, Roche, and SPMSD. S.P. declares that he has a financial relationship (as a scientific advisor, member of the advisory board, or consultant) with Pfizer, Amgen, MSD, Sandoz, Procare Health, Bayer, MSD, Serelys, and Shionogi. Furthermore, as a speaker or member of the advisory board, he has received research grants or honoraria from Servier, Pfizer, Abbott, Shionogi, Amgen, Novo Nordisk, Theramex, Bayer Healthcare, Serelys, and Gedeon Richter. D.D. declares that he has received speaking and consultancy fees from Sanofi Pasteur, MSD, and Procare Health. L.S. declares that he has received speaking and consultancy fees from Shionogi, Iprad, and Procare Health. A.C.L. declares that he has received consultancy fees from Procare Health. S.P.G. declares that she has received travel and/or research grants and/or honoraria for conferences and/or scientific advisory and consultancy fees from Isdín, Pfizer, Servier, Amgen, MSD, Kern-Gynea, Casen Recordati, Sandoz, Procare Health, Bayer, Lacer, Shionogi, GSK, Bioiberica, Theramex, Gedeon Richter, Iprad, Seid, Ordesa, and Zambon. C.V. declares that she has received speaking fees from Procare Health. C.C.-M. declares that she has received speaking fees from Bayer and a grant for congress attendance from GSK. P.C. declares that he has received travel grants, conference registration grants and/or honoraria for conferences, and/or consultancy fees from Genómica, GSK, MSD, Abex, Shionogi, Amgen, Lacer, and Pfizer. J.d.l.F. declares that he has received travel and/or research grants and/or honoraria for conferences and/or consultancy fees from GSK, Merck, Procare Health, Roche, SPMSD, Italfármaco, Adamed, Pfizer, and Effik. J.A.L. declares that he has received honoraria for lectures from Procare Health, Gedeon Richter, and Sanofi. The other authors have declared they have no conflicts of interest.

Supported by Procare Health Iberia SL.

The study has been evaluated and approved by the following institutional review boards: the Comité Ético de Investigación Clínica del Hospital Universitario de la Princesa, the Comité Ético de Investigación Clínica de Clínica Tres Torres-Centre Cardiovascular Sant Jordi, the Comité de Ética de la Investigación Provincial de Málaga, the Comité Ético de Investigación Clínica del Grupo Hospitalario Quirón, the Comité Ético de Investigación Clínica del Hospital General Universitario Gregorio Marañón, the Comité Ético de Investigación Clínica de la Fundació Sanitària del Hospital de la Santa Creu i Sant Pau, the Comité Ético de Investigación Clínica del Hospital General de Alicante, and the Comité Ético Investigación Clínica GAE HCSC Area 7.


1. World Health Organization . Human papillomavirus (HPV) and cervical cancer. Available at: https://www.who.int/news-room/fact-sheets/detail/human-papillomavirus-(hpv)-and-cervical-cancer. Accessed May 21, 2020.
2. Ho GY Bierman R Beardsley L, et al. . Natural history of cervicovaginal papillomavirus infection in young womenN Engl J Med 1998;338:423–8. [PubMed[]
3. McBride E Tatar O Rosberger Z, et al. . Emotional response to testing positive for human papillomavirus at cervical cancer screening: a mixed method systematic review with meta-analysisHealth Psychol Rev 2020;1–35. [PubMed[]
4. Thangarajah F Einzmann T Bergauer F, et al. . Cervical screening program and the psychological impact of an abnormal Pap smear: a self-assessment questionnaire study of 590 patientsArch Gynecol Obstet 2016;293:391–8. [PubMed[]
5. Need for safe, non-surgical treatment for clearing human papilloma virus (HPV). Available at : https://livbio.co.uk/need-for-safe-non-surgical-treatment-for-clearing-human-papilloma-virus-hpv/. Accessed September 17, 2020.
6. Lee JH Kim HL Lee MH, et al. . Asiaticoside enhances normal human skin cell migration, attachment and growth in vitro wound healing modelPhytomedicine 2012;19:1223–7. [PubMed[]
7. Møller MS Goh YJ Viborg AH, et al. . Recent insight in α-glucan metabolism in probiotic bacteriaBiologia 2014;69:713–21. []
8. Couto S. Evaluation of Coriolus versicolor supplementation in HPV patientsClin J of Mycology 2007;2:2–5. []
9. Shukla S Bharti AC Hussain S, et al. . Elimination of high-risk human papillomavirus type HPV16 infection by ‘Praneem’ polyherbal tablet in women with early cervical intraepithelial lesionsJ Cancer Res Clin Oncol 2009;135:1701–9. [PubMed[]
10. Scardamaglia P Carraro C Mancino P, et al. . Efficacia del carbossimetilbetaglucano nella regressione delle alterazioni citologiche cervicali di basso grado HPV correlateMinerva Ginecol 2010;62:389–94. [PubMed[]
11. Egawa N Egawa K Griffin H, et al. . Human papillomaviruses; epithelial tropisms, and the development of neoplasiaViruses 2015;7:3863–90. [PMC free article] [PubMed[]
12. Mitra A MacIntyre DA Lee YS, et al. . Cervical intraepithelial neoplasia disease progression is associated with increased vaginal microbiome diversitySci Rep 2015;5:16865. [PMC free article] [PubMed[]
13. Audirac-Chalifour A Torres-Poveda K Bahena-Román M, et al. . Cervical microbiome and cytokine profile at various stages of cervical cancer: a pilot studyPLoS One 2016;11:e0153274. [PMC free article] [PubMed[]
14. Kyrgiou M, Mitra A, Moscicki AB. Does the vaginal microbiota play a role in the development of cervical cancer? Transl Res 2017;179:168–82. [PMC free article] [PubMed[]
15. Palacios S Losa F Dexeus D, et al. . Beneficial effects of a Coriolus versicolor-based vaginal gel on cervical epithelization, vaginal microbiota and vaginal health: a pilot study in asymptomatic womenBMC Womens Health 2017;17:21. [PMC free article] [PubMed[]
16. Galvez J Rodríguez Nogales A Vezza T, et al. . Effect of a non-hormonal Coriolus versicolor vaginal gel among positive-HPV women with no colposcopy cervical lesions. A pilot study. Poster presentation. European Research Organization on Genital Infection and Neoplasia (EUROGIN). Amsterdam, October 8–11, 2017. Available at: https://secure.key4events.com/key4register/AbstractList.aspx?e=612&preview=1&aig=-1&ai=15955. Accessed May 21, 2020.
17. Gaslain Y Cortés J Dexeus D, et al. . Evaluation of the immunomodulatory properties of a Coriolus versicolor-based vaginal gel in an in vitro human vaginal epithelium model test. Cape Town: Poster presentation at the 31st International Papillomavirus Conference. International Papillomavirus Society; February 28–March 4, 2017. []
18. Gálvez J Vezza T Garrido-Mesa J, et al. . Evaluation of the immunomodulatory properties of a Coriolus versicolor-based gel after its topical administration in the vagina of mice. Lisbon: Poster presented at the 30th International Papilomavirus Conference. International Papillomavirus Society; September 17–21, 2015. []
19. Gálvez J Vezza T Garrido-Mesa J, et al. . Comparative study of the immunomodulatory properties of different Coriolus versicolor-based formulations administered orally or topically in the vagina in healthy mice. Abstract. European Research Organization on Genital Infection and Neoplasia (EUROGIN). Salzburg, June 15–18, 2016. Available at: https://www.eurogin.com/content/dam/Informa/eurogin/previous/EUROGIN-2016.pdf. Accessed May 21, 2020.
20. Solomon D Dravey D Kurman R, et al. Forum Group Members; Bethesda 2001 Workshop . The 2001 Bethesda system: terminology for reporting results of cervical cytologyJAMA 2002;287:2114–9. [PubMed[]
21. Bornstein J Bentley J Bösze P, et al. . 2011 Colposcopic terminology of the International Federation for Cervical Pathology and ColposcopyObstet Gynecol 2012;120:166–72. [PubMed[]
22. Bachmann GA Notelovitz M Kelly SJ, et al. . Long term nonhormonal treatment of vaginal drynessClin Pract Sexuality 1992;8:3–8. []
23. Remor E. Psychometric properties of a European Spanish version of the Perceived Stress Scale (PSS)Span J Psychol 2006;9:86–93. [PubMed[]
24. European Medicines Agency . ICH E9 statistical principles for clinical trials. September 1998 CPMP/ICH/363/96. Available at: https://www.ema.europa.eu/en/ich-e9-statistical-principles-clinical-trials. Accessed September 17, 2020.
25. Castellsagué X Iftner T Roura E, et al. . Prevalence and genotype distribution of human papillomavirus infection of the cervix in Spain: the CLEOPATRE studyJ Med Virol 2012;84:947–56. [PubMed[]
26. Muñoz N Méndez F Posso H, et al. . Incidence, duration, and determinants of cervical human papillomavirus infection in a cohort of Colombian women with normal cytological resultsJ Infect Dis 2004;190:2077–87. [PubMed[]
27. Walboomers JM Jacobs MV Manos MM, et al. . Human papillomavirus is a necessary cause of invasive cervical cancer worldwideJ Pathol 1999;189:12–9. [PubMed[]
28. World Health Organization . WHO Director-General calls for all countries to take action to help end the suffering caused by cervical cancer. Available at: https://www.who.int/reproductivehealth/call-to-action-elimination-cervical-cancer/en/. Accessed May 21, 2020.
29. Darragh TM Colgan TJ Cox JT, et al. . The lower anogenital squamous terminology standardization project for HPV-associated lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical PathologyJ Low Genit Tract Dis 2012;16:205–42. [PubMed[]
30. Matsumoto K Oki A Furuta R, et al. . Predicting the progression of cervical precursor lesions by human papillomavirus genotyping: a prospective cohort studyInt J Cancer 2011;128:2898–910. [PubMed[]
31. Kyrgiou M Athanasiou A Kalliala IEJ, et al. . Obstetric outcomes after conservative treatment for cervical intraepithelial lesions and early invasive diseaseCochrane Database Syst Rev 2017;11:CD012847. [PMC free article] [PubMed[]
32. Torné A del Pino M Cusidó M, et al. . Guía de cribado del cáncer de cuello de útero en España, 2014Prog Obstet Ginecol 2014;57:1–53. []
33. Spanish Ministry of Health . Population screening plans in cancer. Available at: https://www.mscbs.gob.es/profesionales/saludPublica/prevPromocion/cribadoCancer.htm. Accessed May 21, 2020.
34. Bulkmans NW Berkhof J Bulk S, et al. POBASCAM Study Group . High-risk HPV type-specific clearance rates in cervical screeningBr J Cancer 2007;96:1419–24. [PMC free article] [PubMed[]
35. Marín Ortiz E Vázquez Caamaño MP Porto Quintans M, et al. . Efficacy of a Coriolus versicolor-based vaginal gel in high-risk HPV+ women. Preliminary results . Sydney: 32nd International Papillomavirus Conference, IPVC, October 2–6, 2018. Available at: https://ipvc2018.org/PublishingImages/abstract-information/ipvc-2018-submitted-abstracts/IPVC18_-_All_abstracts_for_website.pdf. Accessed May 21, 2020. []
36. Gajino Suárez C. Use and results of a Coriolus versicolor-based vaginal gel in women HPV+ and/or abnormal pap smear attended in a regional Spanish hospital. Preliminary analysis . Sydney: 32nd International Papillomavirus Conference, IPVC, October 2-6, 2018. Available at: https://ipvc2018.org/PublishingImages/abstract-information/ipvc-2018-submitted-abstracts/IPVC18_-_All_abstracts_for_website.pdf. Accessed May 21, 2020. []
37. Riera M Rupérez B Lázaro I, et al. . Coriolus versicolor vaginal gel in the treatment of high-risk positive HPV patients . European Research Organization on Genital Infection and Neoplasia (EUROGIN); December 2–5, 2018; Lisbon. Available at: https://www.eurogin.com/content/dam/Informa/eurogin/2018/pdf/Abstracts-Part3.pdf. Accessed May 21, 2020. []
38. Riera M Rupérez B Lázaro I, et al. . Effect of a multi-ingredient vaginal gel on clearance and/or cytology normalization in high-risk HPV positive patients J Low Genit Tract Dis 2020;24:16. []
39. Cortés J de Santiago J Cos A, et al. . Efficacy of a multi-ingredient vaginal gel in repairing HPV-dependent cervical lesions in real-life: interim analysis. Poster presented at the ASCCP, Scientific Meeting on Anogenital & HPV-Related Diseases; March 31–April 3, 2020. Orlando, FL. []
40. Gaslain Y Cortés J Dexeus D, et al. . Effect of a multi-ingredient vaginal gel in high-risk HPV infected patients: results of different studiesJ Low Genit Tract Dis 2020;24:15–6. []
41. Muñoz N Castellsagué X de González AB, et al. . Chapter 1: HPV in the etiology of human cancerVaccine 2006;24(suppl 3):S3/1–10. [PubMed[]
42. Curry SJ Krist AH Owens DK, et al. US Preventive Services Task Force . Screening for cervical cancer: US Preventive Services Task Force recommendation statementJAMA 2018;320:674–86. [PubMed[]
43. Venetianer R Clarke MA van der Marel J, et al. . Identification of HPV genotypes causing cervical precancer using tissue-based genotypingInt J Cancer 2020;146:2836–44. [PubMed[]


Plaats een reactie ...

Reageer op "Papilocare een vaginale gel gebaseerd op Coriolus versicolor geeft binnen 6 maanden veel betere resultaten bij patienten met aan HPV gerelateerde barmoederhalstumoren."

Gerelateerde artikelen

Gerelateerde artikelen

Papilocare een vaginale gel >> Vitamine A suppletie bij de >> Coriolus Versicolor bestrijdt >> foliumzuur voorkomt en stopt >> Groene thee, gebruikt in vorm >> Complementair: Studiepublicaties >>